Christopher B. Prentiss
Nessuna posizione attualmente
Profilo
Christopher B.
Prentiss worked as a Senior Manager at KPMG LLP from 1997 to 2005.
He then worked as a Controller at MannKind Corp.
and Dynavax Technologies Corp.
in 2012 and 2013 respectively.
From 2013 to 2015, he worked as Vice President-Finance & Controller at InterMune, Inc. He later became the Chief Financial Officer at Adamas Pharmaceuticals LLC from 2019 to 2021.
Mr. Prentiss holds an MBA from Indiana University and an undergraduate degree from Loyola Marymount University.
Precedenti posizioni note di Christopher B. Prentiss
Società | Posizione | Fine |
---|---|---|
ADAMAS PHARMACEUTICALS, INC. | Director of Finance/CFO | 24/11/2021 |
INTERMUNE INC | Comptroller/Controller/Auditor | 01/03/2015 |
DYNAVAX TECHNOLOGIES CORPORATION | Comptroller/Controller/Auditor | 01/06/2013 |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/07/2005 |
MANNKIND CORPORATION | Comptroller/Controller/Auditor | - |
Formazione di Christopher B. Prentiss
Indiana University | Masters Business Admin |
Loyola Marymount University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
MANNKIND CORPORATION | Health Technology |
Aziende private | 3 |
---|---|
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
- Borsa valori
- Insiders
- Christopher B. Prentiss